Recipharm partners with Sato to manufacture product for Japanese market
Recipharm, the contract development and manufacturing organisation (CDMO), has entered into a long term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of Emla™ Patch to Japan.
Sato, based in Tokyo and founded in 1915, is providing effective, safe and high quality products. Emla™ Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato.
Recipharm’s facility in Karlskoga, Sweden will produce and deliver to Sato. After a successful launch in Japan, it is expected that the annual volumes of Emla™ Patch to Sato will be a significant addition to the present production at the Karlskoga facility.
Ingela Palmkvist, General Manager at Recipharm in Karlskoga says: “We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further. We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies.”
Ingela Palmkvist, General Manager, email@example.com , +46 (0)586 68 293
Erik Haeffler, Vice President Manufacturing Services & Head of CSR, firstname.lastname@example.org , + 46 (0)8 6025 285
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com , + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
About Sato Pharmaceuticals
Sato Pharmaceuticals was founded in 1915 and is based in Tokyo, Japan, with branches in Europe, US and Canada. Sato Pharmaceutical’s main priority has been to serve customer health by providing OTC products that are precisely designed to fit the real needs of the market. The company has kept this focus over the years by creating an ongoing series of top products as it continues to grow and succeed. The goal is to help people to live healthier, happier lives. Sato Pharmaceuticals celebrated its 100th anniversary in 2015. Based on the corporate philosophy of Healthcare Innovation, Sato will work to contribute to consumers’ health by providing products such as OTC and ethical pharmaceuticals.
For further information, please visit www.sato-seiyaku.co.jp
* TM owned by AstraZeneca Pharmaceuticals: EMLA product licensed to Sato in Japan and trademark used under license from AstraZeneca
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00